p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study - PubMed (original) (raw)

p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study

F Buttitta et al. Br J Cancer. 1997.

Free PMC article

Abstract

Chemotherapeutic management of ovarian cancers is a difficult task as these neoplasms show significant differences in chemosensitivity, even if they share identical clinicopathological features. The present study was undertaken to investigate the prognostic and predictive role of p53 alterations in ovarian cancer. To this end, using different technical approaches, i.e. genetic and immunohistochemical analyses, we analysed a series of 68 ovarian neoplasms including 15 low malignant potential (LMP) tumours and 53 invasive carcinomas. We never observed p53 abnormalities in LMP tumours. p53 alterations were present only in invasive ovarian carcinomas, and they were detected much more frequently in tumours characterized by high histological grade (P = 0.01) and advanced-stage disease (P = 0.006 and P = 0.05 for gene mutations and protein expression respectively). For 33 patients with invasive ovarian cancer, information was available concerning response to cisplatin-based chemotherapy. A strong correlation (P = 0.001) has emerged between p53 alterations and response to chemotherapy; only one (14%) of seven patients who had a pathological complete response to antiblastic drugs showed p53 aberrations, whereas 18 (82%) of 22 cases with partial response and all of the four non-responsive patients scored positive for p53 abnormalities. We also observed that patients with p53 mutations had a significantly shorter progression-free survival than patients with p53-negative tumours (P = 0.05). Taken together, our results strongly suggest that in epithelial ovarian malignancies tumours showing p53 aberrations are significantly less sensitive to chemotherapy and more aggressive than those with functional p53. Thus, a routine analysis of this gene could have profound implications for the treatment of ovarian cancer.

PubMed Disclaimer

Similar articles

• Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer.
  Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, Jones LA, El-Naggar A, Minguillon C, Schönborn I, Reich O, Kreienberg R, Lichtenegger W, Press MF. Reles A, et al. Clin Cancer Res. 2001 Oct;7(10):2984-97. Clin Cancer Res. 2001. PMID: 11595686
• p53 mutations in epithelial ovarian cancers: possible role in predicting chemoresistance.
  Laframboise S, Chapman W, McLaughlin J, Andrulis IL. Laframboise S, et al. Cancer J. 2000 Sep-Oct;6(5):302-8. Cancer J. 2000. PMID: 11079169
• Expression and mutation of p53 in tumor effusion cells of patients with ovarian carcinoma: response to cisplatin-based chemotherapy.
  Bar JK, Harłozińska A, Popiela A, Noga L. Bar JK, et al. Tumour Biol. 2001 Mar-Apr;22(2):83-91. doi: 10.1159/000050601. Tumour Biol. 2001. PMID: 11125280
• A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors.
  Kmet LM, Cook LS, Magliocco AM. Kmet LM, et al. Cancer. 2003 Jan 15;97(2):389-404. doi: 10.1002/cncr.11064. Cancer. 2003. PMID: 12518363 Review.
• The clinical significance of p53 aberrations in human tumours.
  Bosari S, Viale G. Bosari S, et al. Virchows Arch. 1995;427(3):229-41. doi: 10.1007/BF00203389. Virchows Arch. 1995. PMID: 7496591 Review.

Cited by

• P53, bcl-2, ki-67 li (labeling index) status in benign, proliferative, and malignant ovarian surface epithelial neoplasms.
  Gursan N, Sipal S, Calik M, Gundogdu C. Gursan N, et al. Eurasian J Med. 2009 Apr;41(1):10-4. Eurasian J Med. 2009. PMID: 25610057 Free PMC article.
• NSC109268 potentiates cisplatin-induced cell death in a p53-independent manner.
  Shankar E, Basu C, Adkins B, Siede W, Basu A. Shankar E, et al. J Mol Signal. 2010 May 10;5:4. doi: 10.1186/1750-2187-5-4. J Mol Signal. 2010. PMID: 20459745 Free PMC article.
• Chemoresistance in human ovarian cancer: the role of apoptotic regulators.
  Fraser M, Leung B, Jahani-Asl A, Yan X, Thompson WE, Tsang BK. Fraser M, et al. Reprod Biol Endocrinol. 2003 Oct 7;1:66. doi: 10.1186/1477-7827-1-66. Reprod Biol Endocrinol. 2003. PMID: 14609433 Free PMC article. Review.
• TP53 mutations in early-stage ovarian carcinoma, relation to long-term survival.
  Wang Y, Helland A, Holm R, Skomedal H, Abeler VM, Danielsen HE, Tropé CG, Børresen-Dale AL, Kristensen GB. Wang Y, et al. Br J Cancer. 2004 Feb 9;90(3):678-85. doi: 10.1038/sj.bjc.6601537. Br J Cancer. 2004. PMID: 14760384 Free PMC article.
• Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors.
  McDonald AC, Brown R. McDonald AC, et al. Br J Cancer. 1998 Sep;78(6):745-51. doi: 10.1038/bjc.1998.571. Br J Cancer. 1998. PMID: 9743293 Free PMC article.

References

1. 1. Genomics. 1989 Nov;5(4):874-9 - PubMed
2. 1. Cancer Res. 1996 Feb 15;56(4):689-93 - PubMed
3. 1. Gynecol Oncol. 1990 Sep;38(3):340-2 - PubMed
4. 1. Biochem Pharmacol. 1990 Nov 15;40(10):2353-62 - PubMed
5. 1. Cancer Res. 1991 Jun 1;51(11):2979-84 - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Europe PubMed Central
  • Nature Publishing Group
  • PubMed Central

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal